Josie’s Experience Using LDN and Diet for Crohn’s Disease, Asthma, and Rheumatoid Arthritis
Josie’s Experience Using LDN and Diet for Crohn’s Disease, Asthma, and Rheumatoid Arthritis Josie from the United States shared her experience of using LDN for Crohn’s disease, asthma, and rheumatoid arthritis. She began using LDN after struggling with Crohn’s disease for several years and undergoing multiple surgeries, as traditional medications were not effective in […]
Melanie’s MCAS, POTS, Sjogren’s, Fibromyalgia, Asthma, & Hashimoto’s Story
Melanie, a resident of Canada, went through a challenging journey of coping with multiple health conditions such as MCAS, POTS, Sjogren’s, Fibromyalgia, Asthma, and Hashimoto’s. It’s undoubtedly difficult to manage so many health issues simultaneously. However, Melanie found that once she was diagnosed with MCAS and learned how to control it, she observed an improvement […]
Will Low Dose Naltrexone (LDN) help with other conditions in addition to what I’m taking it for?
The LDN Book 3 (LDN; low dose naltrexone)
The LDN 3: To Purchase with discounts before 1st September 2022 Go to ldnresearchtrust.org/ldn-book-3 for full details
Dosing of Low Dose Naltrexone (LDN)
Sleep Issues and Low Dose Naltrexone (LDN)
The Immune System and Low Dose Naltrexone (LDN)
LDN Webinar 18 May 2022 (LDN; low dose naltrexone)
LDN Webinar 18 May 2022 (LDN; low dose naltrexone) LDN Questions Answered Live by Pharmacist Dr Masoud Rashidi – LDN Specialist Dr Sato-Re Dr Mathewson Sponsored by Innovative Compounding Pharmacy icpfolsom.com
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone (News)
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone GlobalNewswire 27 April 2022 https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html Statera Biopharma, a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced an agreement with Immune Therapeutics to sell Statera’s rights to any product containing met-enkephalin or low-dose naltrexone as […]